Eli Lilly is locking down on its rapid expansion strategy with a second deal this week – joining forces with artificial intelligence (AI) biotech, Profluent, to develop recombinases for large-scale ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent, the AI-first protein design company, today announced Protein2PAM, the first in a series of AI models that will broadly focus on protein-DNA interactions ...

Collaboration combines Profluent's frontier AI platform with Lilly's leading capabilities in genetic medicines AI-designed recombinases aim to unlock kilobase-scale DNA editing capabilities across ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established ...

Gemma Biotherapeutics ("GEMMABio"), a clinical-stage, global, genetic medicines company, today announced that it has been awarded funding by the Advanced Research Projects Agency for Health (ARPA-H).

Ali Madani, PhD, CEO of Profluent, says there’s an urgent need to move away from the time-consuming slog of random therapeutic discovery and into artificial intelligence (AI)-based bespoke design.

(Bloomberg) -- Eli Lilly & Co. has signed a deal with the AI startup Profluent Inc. worth up to $2.25 billion to find new ways to edit DNA, the company’s latest bet that artificial intelligence can ...

Profluent has raised $106 million to scale up use of its AI models for biology in drug development and agriculture. Ali Madani started thinking about how AI could be programmed for biology in 2020, ...

Last year, Salesforce, the company best known for its cloud sales support software (and Slack), spearheaded a project called ProGen to design proteins using generative AI. A research moonshot, ProGen ...

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly (LLY.N), opens new tab worth up ‌to $2.25 billion to develop ...

Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development of novel gene editing therapies This new Pin-point ...